Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allostem Sheet general drug use-results survey
jRCT2033260573Recruiting
- Sponsor
- Ishin Pharma
- Start
- Oct 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and epidermolysis bullosa simplex (EBS), sponsored by Ishin Pharma. Primary endpoints: Number and incidence of serious adverse events, Number and incidence of adverse drug reactions and 5 more. Started Oct 2026; status: recruiting.
02
Conditions
dystrophic epidermolysis bullosa (DEB)junctional epidermolysis bullosa (JEB)epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on jRCT2033260573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260573.